Calithera Biosciences Presents New Preclinical Data for CB-708 at AACR Annual Meeting 2019
April 02 2019 - 7:05AM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, announced new preclinical data for the
company’s CD73 inhibitor CB-708. The data will be presented today
at the American Association for Cancer Research (AACR) Annual
Meeting 2019 in Atlanta, Georgia.
CB-708 is a selective, oral inhibitor of CD73, an enzyme that
synthesizes the immunosuppressive agent adenosine and is
over-expressed in multiple tumor types. By blocking adenosine
production in the tumor, CB-708 is designed to enhance T-cell
activation leading to anti-tumor activity. Calithera plans to
initiate clinical development of the compound in the second half of
2019.
“We are excited to share these new preclinical data on CB-708,
our small-molecule CD73 inhibitor designed to be dosed orally in
patients, and to demonstrate our progress in advancing this
compound into the clinic,” said Susan Molineaux, PhD, president and
chief executive officer of Calithera. “CB-708 has the potential to
be combined with immunotherapy or chemotherapy to activate the
immune system and improve outcomes for patients with a variety of
cancers.”
The preclinical data being presented today by Clarissa Lee,
Ph.D. (Abstract #4134, Section 25, Board 8), demonstrate that
CB-708 is a potent and selective inhibitor of CD73 that has
immune-mediated, single agent activity in syngeneic mouse tumor
models. In addition, in pre-clinical studies CB-708 is
well-tolerated and shows enhanced anti-tumor activity when combined
with either an anti-PD-L1 immunotherapy or with chemotherapeutic
agents such as oxaliplatin or doxorubicin.
Additional meeting information can be found at the AACR website
www.aacr.org. The CB-708 poster presentation will be available at
www.calithera.com on the Publications page.
About CB-708 and CD73
CB-708 is an orally bioavailable small molecule inhibitor of
CD73, an enzyme in the tumor microenvironment that produces
adenosine, a powerful inhibitor of immune function in tumors. CD73
is expressed across a wide range of tumor types and
tumor-infiltrating leukocytes. Expression of CD73 often correlates
with poor prognosis in patients with cancer. Blockade of adenosine
production by CD73 inhibition is expected to reverse
immunosuppression in the tumor microenvironment and enhance the
immune system’s ability to fight the cancer.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused
on fighting cancer and other life-threatening diseases by
discovering, developing, and commercializing novel small molecule
drugs that target tumor and immune cell metabolism. Calithera is
headquartered in South San Francisco, California. For more
information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the timing of
Calithera’s clinical trials, the review, registration and approval
of CB-708 by the FDA, and the safety and efficacy of CB-708.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. The potential product
candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such
product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with
respect to any of the foregoing matters may have a negative effect
on Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found
in Calithera's periodic filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking statements are not
guarantees of future performance and speak only as of the date
hereof, and, except as required by law, Calithera disclaims any
obligation to update these forward-looking statements to reflect
future events or circumstances.
SOURCE: Calithera Biosciences, Inc.
CONTACT: Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Sep 2023 to Sep 2024